Rothschild Redburn initiates Certara stock with Buy rating on biosimulation leadership

Rothschild Redburn initiated coverage of Certara with a Buy and $10 price target (about 25% upside from $8.03), highlighting the company's leadership in biosimulation—Simcyp and Phoenix have supported approvals for more than 125 products and helped drive 11.5% revenue growth TTM—while the 2024 Chemaxon acquisition and the new CertaraIQ platform are intended to deepen penetration in discovery/pre‑clinical stages and enable cross‑selling. Certara reported a marginal Q3 2025 beat (EPS $0.11 vs. $0.1099; revenue $104.6m vs. $104.64m) but shares fell in after‑hours trading; InvestingPro flags the stock as undervalued with RSI in oversold territory and analyst targets as high as $16, suggesting upside if management can expand earlier‑stage adoption and convert its platform advantage into sustained revenue growth.

Analysis

Rothschild Redburn initiated coverage of Certara (NASDAQ:CERT) with a Buy rating and a $10.00 price target, implying roughly 25% upside from the current $8.03 and noting the stock trades near its 52‑week low; InvestingPro labels the name undervalued, RSI is in oversold territory, and some analyst targets reach as high as $16. The coverage highlights Certara’s leadership in biosimulation—its Simcyp and Phoenix products have supported approvals for over 125 products—and cites 11.47% revenue growth over the last twelve months as evidence of commercial traction.

Certara’s 2024 acquisition of Chemaxon and the launch of the CertaraIQ quantitative systems pharmacology platform are positioned to expand penetration into discovery and pre‑clinical stages and create cross‑selling opportunities, which Rothschild Redburn identifies as the primary path to sustain growth. These strategic moves address a clear go‑to‑market gap: existing strong adoption in clinical phases needs to be complemented by earlier‑stage uptake to drive a step change in revenue expansion.

Q3 2025 results produced a marginal beat—EPS $0.11 versus $0.1099 and revenue $104.6 million versus $104.64 million—but the stock declined in after‑hours trading, underscoring sensitivity to near‑term execution and sentiment despite meeting estimates. Absence of additional M&A announcements or analyst ratings changes in the report suggests upside remains contingent on converting product leadership and recent acquisitions into measurable discovery/preclinical revenue and improved market sentiment.

Key Decisions for Investors

• Consider a selective, size‑controlled buy given a Buy initiation, $10 price target and valuation signals (RSI oversold, InvestingPro undervalued), but limit position size until evidence of discovery/preclinical traction emerges
• Monitor leading indicators: cross‑sell metrics and revenue contribution from CertaraIQ and Chemaxon integration, sequential revenue/margin trends, and commentary on adoption in discovery/preclinical stages as triggers to increase exposure
• Given the marginal beat and after‑hours selloff, use tactical entry methods (staggered buys or limit orders) or hedges if exposure is material, and reassess if subsequent quarters fail to show expansion beyond clinical‑phase penetration